Five Common Symptoms Of Stomach Cancer That Should Not Be Ignored

Updated Dec 13, 2024 | 02:53 PM IST

SummaryStomach or gastric cancer is a type of cancer that develops in the lining of the stomach. There are certain symptoms like vomiting blood, abdominal pain that should immediately be addressed.
Stomach cancer

Stomach cancer (credit: canva)

Stomach cancer is a type of cancer that develops in the lining of the stomach. Also, known as Gastric cancer, it affects the elderly more than the adult. According to the American Cancer Society, about 6 of every 10 people diagnosed with stomach cancer each year are 65 or older. Also, the lifetime risk of developing stomach cancer is higher in men (about 1 in 101) than in women (about 1 in 155).

A health expert, speaking to a leading media house, emphasized five common symptoms of stomach cancer that should not be ignored:

1. Unexplained weight loss: Losing weight without trying or experiencing an unexplained drop in appetite, which may signal cancer progression.

2. Pain in the upper part of the abdomen: Persistent or occasional pain in the stomach area, often after eating, can become more severe as the condition progresses.

3. Frequent vomiting after meals: Nausea, sometimes accompanied by vomiting, may occur especially after meals and is linked to cancer blocking or irritating the stomach.

4. Vomiting blood, which may appear coffee-colored: This can indicate bleeding in the stomach, often caused by ulcers or tumors, and requires immediate medical attention.

5. Black, tarry stools: This occurs when blood from the stomach is digested and passed through the intestines, signaling potential internal bleeding

There are also other concerning signs that should not be overlooked such as jaundice, unexplained weight loss, early onset of diabetes, dark stools, and loss of appetite. Health experts strongly advise seeking immediate medical attention if you notice any of these symptoms. If you or a loved one experience these signs, it's crucial to visit a physician for a thorough evaluation to rule out serious underlying health conditions.

How Does Stomach Cancer Spread?

Oncologist Dr Pankaj Kumar Pande, Director–Surgical Oncology, Max Super Specialty Hospital, Shalimar Bagh, Delhi explained that this form of cancer spreads through three main pathways: Direct spread, lymphatic spread, and bloodstream.

1. Direct Spread: In its early stages, stomach cancer can invade nearby tissues and grow into the deeper layers of the stomach or spread to surrounding organs such as the oesophagus, liver, pancreas, or intestines.

2. Lymphatic Spread: Cancer cells can travel through the lymphatic system. The most common areas affected are the regional lymph nodes near the stomach, particularly those around the liver and diaphragm.

3. Bloodstream: "Cancer cells can enter the bloodstream and travel to distant parts of the body," which is a common route for stomach cancer to metastasize to distant organs.

He further explained that cancerous cells spread from the original tumour to other parts of the body through a process called Metastasis. The most common sites for the spread are the liver, lymph nodes, peritoneum, lungs, bones, and ovaries.

End of Article

Not Just US, Mexico & Bolivia Also Lose Measles-Free Status: RFK Jr & CDC Chief Respond

Updated Nov 18, 2026 | 08:13 AM IST

SummaryThe Pan American Health Organization (PAHO) recently announced that the United States, Mexico and Bolivia have lost their measles-free status as they failed to interrupt transmission over a period of 12 months.
Not Just US, Mexico & Bolivia Also Lose Measles-Free Status: RFK Jr & CDC Chief Respond

Credit: AI image

The United States is not the only country to lose its measles elimination status this year. Mexico and Bolivia have also lost the status after the highly contagious virus continued spreading for more than 12 months, according to the Pan American Health Organization (PAHO).

The decision was formally announced on November 17, 2026 by PAHO's independent Regional Monitoring and Re-Verification Commission, which reviewed measles data from 47 countries and territories across the Americas.

The United States had maintained its measles elimination status since 2000, while Mexico and Bolivia had also previously interrupted sustained local transmission. The latest development marks a setback in efforts to control a disease that can be prevented through vaccination.

The announcement comes as measles cases continue to rise across the region. As of November 13, 2026, the Americas had reported 58,213 confirmed cases and 82 deaths, compared with 12,806 cases during the same period in 2025.

Three Countries In Americas Lose Measles-Free Status

Also read: 112 Pregnant Women, 13 Newborns Infected With Measles In US Since 2025: CDC

According to PAHO, a country loses its measles elimination status when the same measles virus genotype and lineage circulates continuously within its borders for at least 12 months. This indicates that the virus has re-established endemic transmission rather than appearing only through isolated cases imported from other countries.

According to PAHO, the sustained transmission periods in the three countries began on different dates:

  • United States: The outbreak began on January 20, 2025, reaching the 12-month threshold on January 20, 2026.
  • Mexico: The outbreak began on February 1, 2025, reaching the one-year mark on February 1, 2026.
  • Bolivia: The outbreak began on April 16, 2025, marking one year of continued transmission on April 16, 2026.

Losing elimination status does not mean that measles is spreading everywhere within these countries. It means that the same virus lineage has continued circulating locally for at least a year.

The Americas had previously lost its regional measles elimination status in November 2025, after Canada reported to have sustained transmission for more than 12 months. The region had first eliminated measles in 2016 and regained that achievement in 2024 after stopping transmission in Venezuela and Brazil.

What Did HHS Secretary Robert F Kennedy Jr And CDC Chief Dr Erica Schwartz Say?

Also read: US Loses Measles Elimination Status After 26 Years: What Does It Mean?

After PAHO's announcement, US Health and Human Services Secretary Robert F. Kennedy Jr and Centers for Disease Control and Prevention (CDC) Director Dr Erica Schwartz issued separate statements.

Kennedy said the administration would continue working to control outbreaks and restore the country's elimination status.

"We will stop measles outbreaks, protect American families, and work to regain U.S. measles elimination status," he said in a statement. He also expressed his support for vaccination, adding, "I continue to recommend MMR vaccination as the most effective way to prevent measles."

Kennedy attributed gaps in childhood immunisation to disruptions during the COVID-19 pandemic which affected routine vaccination programmes in the US and other countries.

He also said that approximately $100 million in additional CDC funding has been provided since August to strengthen measles prevention and outbreak response. The funding is intended to support state and local health departments, improve surveillance and help close vaccination gaps.

CDC Director Dr Schwartz said the loss of the designation would not change the agency's approach to controlling the disease.

"The measles elimination designation is not what protects Americans. Vaccination does. We know where transmission is occurring and we've invested $100 million in state and local health departments to reach those communities," she said.

"Losing a designation doesn't mean we abandon an evidence-based approach. It means we remain focused on stopping outbreaks."

Also read: RFK Jr's Vaccine Controversy: What His Samoa Trip Has To Do With 83 Measles Deaths

Measles Resurgence In The Americas

The latest PAHO figures highlight the scale of the resurgence. The region recorded more than four times as many confirmed measles cases by November 13, 2026 as during the corresponding period in 2025.

Mexico has reported more than 13,900 confirmed cases so far in 2026, the highest annual total since the 1989-90 epidemic. The US has recorded more than 5,400 cases and 10 deaths, its highest in more than 35 years. Bolivia has reported more than 100 cases.

Amid the resurgence, a CDC report has identified 112 measles infections among pregnant women in the US between January 2025 and September 2026, along with 13 cases of congenital measles in newborns. Nearly all the women were unvaccinated or had an unknown vaccination status.

Measles is among the most contagious infectious diseases. One infected person can transmit the virus to as many as 18 people who are susceptible to infection.

The disease typically causes fever, cough, a runny nose, red and watery eyes, followed by a characteristic skin rash. However, it can also lead to serious complications, including pneumonia, brain inflammation (encephalitis), blindness and death. It can also weaken the immune system for months after infection.

Can The Countries Regain Measles Elimination Status?

PAHO expects the US, Mexico and Bolivia to submit plans outlining how they plan to interrupt transmission and strengthen measles vaccination and surveillance.

The organisation has called on countries across the Americas to achieve and maintain at least 95% coverage with both doses of the measles vaccine.

The MMR vaccine, which protects against measles, mumps and rubella, remains the most effective way to prevent measles.

End of Article

US FDA Approves First Drug To Cut Death Risk By 55% In Niemann-Pick Patients: What Is The Rare Disease?

Updated Nov 18, 2026 | 07:02 AM IST

SummaryNiemann-Pick disease type C (NPC) is a rare inherited disorder that affects the body's ability to process cholesterol. Lembaz addresses this underlying cause, extending life expectancy.
US FDA Approves First Drug To Cut Death Risk By 55% In Niemann-Pick Patients: What Is The Rare Disease?

Credit: AI image

The US Food and Drug Administration (FDA) has granted approval to a new drug that could help patients with a rare and life-threatening genetic disorder live longer. The treatment, Lembaz (adrabetadex), is the first drug proven to reduce the risk of death in patients with infantile-onset Niemann-Pick disease type C (NPC).

Announced on November 17, 2026, the approval marks an important development for families affected by the rare disease, which causes progressive neurological damage and can significantly shorten life expectancy.

Lembaz is approved for adults and children weighing at least 7 kg (approximately 15 pounds) whose neurological symptoms began before the age of six. It is administered as an injection directly into the fluid surrounding the spinal cord, a procedure known as an intrathecal injection, every two weeks.

"For the first time, there is a treatment shown to help adults and children with this serious disease live longer," said Acting FDA Commissioner Kyle Diamantas.

Lembaz Reduces Risk Of Death By 55% In Niemann-Pick Patients

Also read: Trials For Deadly Childhood Brain Cancer Stalled After Trump Administration Shuts Down 27-Year Research Consortium

The FDA's approval was based on data from 36 patients treated with Lembaz across three clinical studies. Their outcomes were compared to an external control group of patients who had not received the treatment.

The analysis found that patients who received Lembaz had a 55% lower risk of death compared to the control group.

The median overall survival was 8.5 years among patients treated with Lembaz compared to 4.9 years in the control group.

The benefit was observed regardless of whether patients were also receiving miglustat, another medicine used to manage NPC.

What Is Niemann-Pick Disease Type C?

Also read: Childhood Obesity: Wegovy Cuts BMI By 10% In Children As Young As 6; What Are The Risks?

Niemann-Pick disease type C is a rare inherited disorder that affects the body's ability to process cholesterol and other fatty substances inside cells.

The condition is caused by changes in either the NPC1 or NPC2 gene. These genes produce proteins that help move cholesterol and other lipids within cells. When these proteins do not function properly, fatty substances accumulate inside cells, affecting organs like liver, spleen and brain. Over time, this causes progressive damage to the nervous system.

Patients may experience difficulties with movement, balance, coordination, speech and swallowing. Some may also face seizures, cognitive difficulties and problems controlling eye movements.

The disease affects approximately one in 150,000 people, according to the FDA. Its symptoms and severity can vary depending on when the disease begins.

Infantile-Onset Niemann-Pick Disease Can Be Severe

Also read: 112 Pregnant Women, 13 Newborns Infected With Measles In US Since 2025: CDC

Infantile-onset NPC refers to cases in which neurological symptoms start before the age of six. These patients experience a more aggressive disease as they face rapid progressive neurological deterioration and a shorter life expectancy.

As the disease advances, children may gradually lose the ability to walk, speak and swallow independently. Difficulties with swallowing can also increase the risk of respiratory complications.

There is currently no cure for NPC, making treatments that can slow disease progression or improve survival important.

More About Lembaz

Lembaz contains adrabetadex, a cyclodextrin-based medicine made to address the underlying cholesterol processing defect in NPC.

In simple terms, the drug helps move cholesterol trapped inside cells, especially brain cells, so that it can be transported to areas where it is needed.

By targeting this underlying problem, the treatment aims to reduce the cellular damage that comes with the disease.

According to the FDA, hearing impairment, including permanent hearing loss, could be one of the side effects of Lembaz. Hence, patients must undergo hearing assessments before starting the drug and regularly throughout the course.

Other common side effects include balance and coordination problems, fatigue, vomiting, back pain, headache, fever, diarrhoea, nausea and cough.

End of Article

112 Pregnant Women, 13 Newborns Infected With Measles In US Since 2025: CDC

Updated Nov 18, 2026 | 02:00 AM IST

SummarySummary: A CDC-led report identified 112 measles infections among pregnant women and 13 cases of congenital measles in newborns in the US between January 2025 and September 2026. Nearly all infected women were unvaccinated or had an unknown vaccination status, highlighting the risks of declining immunization amid ongoing outbreaks.
112 Pregnant Women, 13 Newborns Infected With Measles In US Since 2025: CDC

Credit: AI Image

The US has lost its measles elimination status after 26 years, with Bolivia and Mexico also losing the designation, the Pan American Health Organization (PAHO) announced on Tuesday. The decision follows more than 12 months of continuous measles transmission in the US.

Amid the resurgence, a CDC-led report has identified 112 measles infections among pregnant women in the US between January 2025 and September 2026, along with 13 cases of congenital measles in newborns. Nearly all the women were unvaccinated or had an unknown vaccination status.

The actual number of infections among pregnant women may be higher. A separate CIDRAP News investigation based on state health department data identified at least 167 pregnant women infected in 2025 and 2026.

Measles In Unvaccinated Women

Also Read: What Happens After Measles Infection? The Hidden Risks That Can Last For Years

The CDC-led report, published in NEJM Evidence journal, found that 108 (96%) of the 112 cases occurred during outbreaks involving 50 or more cases.

Of the infected women, 110 (98%) had received no MMR vaccine doses or had an unknown vaccination status.

Twenty-six women (23%) were hospitalized for reasons unrelated to childbirth, while 11 (10%) developed pneumonia.

“Even though measles is an old disease, measles in pregnancy is an emerging area that we need to learn about,” said Michelle Barton, a professor at the Schulich School of Medicine & Dentistry at Western University.

Measles In Newborns

Read More: Congenital Measles Reported In Pennsylvania For First Time In Decades: What Parents Should Know

The report recorded 21 pregnancy outcomes within 14 days of maternal rash onset: 19 live births and two pregnancy losses, including one miscarriage and one stillbirth.

Eight babies were born prematurely, and eight required admission to a neonatal intensive care unit (NICU).

The report noted that 13 babies had congenital measles and tested positive for the virus. Of these, six developed symptoms, including one with signs compatible with meningoencephalitis, a potentially life-threatening inflammation of the brain and surrounding membranes.

The authors said the outbreaks highlighted measles' risks to maternal and newborn health.

Many doctors and nurses treating these patients have never encountered measles, relying largely on medical training and professional guidelines to manage the infections.

The CDC recommends intravenous immunoglobulin as post-exposure prophylaxis for pregnant women without documented MMR vaccination or other evidence of immunity who are exposed to measles.

Newborns exposed to measles in the womb should also receive immunoglobulin at birth. Congenital measles can cause severe neurological complications, including subacute sclerosing panencephalitis (SSPE), a rare, progressive brain disorder.

US Loses Measles Elimination Status After 26 Years

The US is experiencing its highest measles burden in more than three decades. Since 2025, approximately 7,700 people have been infected and 13 have died, according to the figures cited in the report.

As of November 12, the CDC had confirmed 5,412 cases and six deaths in 2026. States had reported 10 deaths.

The rise in infections has coincided with declining vaccination rates and growing vaccine hesitancy. US Health Secretary Robert F. Kennedy Jr. has repeatedly questioned measles vaccine safety without scientific evidence supporting those claims.

The CDC said it would work to stop outbreaks and regain elimination status by supporting states and providing sustained national leadership.

"The measles elimination designation is not what protects Americans; vaccination does," CDC Director Erica Schwartz said.

End of Article